Related Experiment Video
Updated: Feb 6, 2026
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
[GUIDELINES FOR DIAGNOSIS AND TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROME]
Insights
Croatian guidelines for myelodysplastic syndrome (MDS) diagnosis and treatment are established. These guidelines address MDS, a stem cell disorder, and its risk stratification for effective patient management.
Area of Science:
- Hematology
- Oncology
Background:
- Myelodysplastic syndrome (MDS) is a heterogeneous clonal hematopoietic stem cell disorder.
- MDS is characterized by ineffective hematopoiesis, dysplasia, cytopenia, and risk of transformation to acute myeloid leukemia (AML).
Purpose of the Study:
- To establish Croatian guidelines for the diagnosis and treatment of myelodysplastic syndrome (MDS).
Main Methods:
- Diagnosis relies on morphological assessment of hematopoietic cells.
- Cytogenetic analysis and bone marrow flow cytometry supplement morphological diagnosis.
- Risk stratification utilizes scoring systems based on disease progression and survival.
Main Results:
- Guidelines developed by the Croatian Cooperative Group for Hematologic Diseases (CROHEM) and the Croatian Society for Haematology.
- Treatment strategies are tailored to disease risk factors and individual patient risk.
Conclusions:
- Standardized guidelines are crucial for consistent diagnosis and risk-adapted treatment of MDS.
- Effective management of MDS requires integrating diagnostic findings with prognostic scoring systems.
Abstract:
Myelodysplastic syndrome Working Group of the Croatian Cooperative Group for Hematologic Diseases (CROHEM), Referral center of the Ministry of Health of the Republic of Croatia for diagnostics and treatment of MDS, as well as the Croatian Society for Haematology of the Croatian Medical Association have made Croatian guidelines for diagnosis and treatment of myelodysplastic syndrome (MDS). MDS is a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, dysplasia, cytopenia and risk of transformation to acute myeloid leukemia (AML). Diagnosis is based on morphological characteristics of hematopoietic cells supplemented with the cytogenetic analysis and bone marrow flow cytometry. Due to great differences in the natural course of the disease, i.e. time to progression to AML and the expected time of survival several scoring systems have been developed to determine the disease risk. The treatment of patients with MDS is based on the risk factors of the disease as well as the individual risk of treatment.
Related Concept Videos
01:24Nursing Process for Patient and Caregiver Teaching I: Assessment and Diagnosis
It is critical to determine the patient's learning needs during the assessment. Determination of learning needs compounds data...
01:11Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
01:30Guidelines for Nursing Documentation I
Factual:
The following points emphasize the significance of upholding accurate and unbiased documentation in healthcare.
01:23Guidelines for Sketching a Curve
01:26Guidelines for Nursing Documentation II
Timely documentation is crucial to ensure continuity of care for patients. Any delays in recording or reporting medical information can result in medical errors and even adverse patient outcomes. From medication administration to diagnostic test results, every detail must be accurately and promptly documented to provide the best possible care for patients.
01:06Legal Guidelines for Documentation